DELACIA WILLIAMS: Open Payments
NPI 1760267801 · MANDEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,057 in 138 payments from 13 companies in 2025. Trend: 2023 $320 · 2024 $2,076 · 2025 $3,057
Food & beverage: $2,945Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $686 |
| ABBVIE INC. | 23 | $506 |
| Teva Pharmaceuticals USA, Inc. | 12 | $318 |
| Janssen Pharmaceuticals, Inc | 12 | $310 |
| Otsuka America Pharmaceutical, Inc. | 13 | $286 |
| E.R. Squibb & Sons, L.L.C. | 12 | $278 |
| Axsome Therapeutics, Inc. | 13 | $196 |
| Lundbeck LLC | 11 | $167 |
| Collegium Pharmaceutical, Inc. | 1 | $122 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
Products named: CAPLYTA, VRAYLAR, COBENFY, REXULTI, Auvelity, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across LA — which companies pay providers there.
